This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IQVIA (IQV) Climbs 17% in 3 Months: Here's What to Know
by Zacks Equity Research
IQVIA (IQV) benefits from revenue growth and disciplined cost management.
IQVIA (IQV) Stock Gains 8% in a Month: Here's What to Know
by Zacks Equity Research
IQVIA (IQV) aims at market expansion through innovation and service improvements.
Why Is IQVIA (IQV) Up 12.4% Since Last Earnings Report?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA (IQV) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IQVIA Holdings (IQV) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
IQVIA Holdings' (IQV) revenues increase year over year in third-quarter 2023.
IQVIA Holdings (IQV) Q3 Earnings Surpass Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 1.22% and 1.21%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Shockwave Medical (SWAV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why IQVIA (IQV) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
IQVIA (IQV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IQVIA (IQV) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.
IQVIA Holdings (IQV) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IQVIA (IQV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for West Pharmaceutical (WST) in Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
4 Medical Product Stocks Set to Outpace Q3 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EW, PODD, DXCM and IQV are poised ahead of their earnings release.
Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
IQVIA (IQV) and argenx Partner to Advance Autoimmune Care
by Zacks Equity Research
IQVIA (IQV) and argenx expand collaboration to advance rare autoimmune treatments through innovative pharmacovigilance.
Here's Why Investors Should Retain IQVIA (IQV) Stock Now
by Zacks Equity Research
An addressable market size and strong healthcare-specific global IT infrastructure boost IQVIA (IQV).
IQVIA (IQV) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA (IQV) Stock Improves 8% in Three Months: Here's How
by Zacks Equity Research
IQVIA (IQV) aims at market expansion through innovation and service improvements.
IQVIA Holdings' (IQV) Q2 Earnings Beat Estimates, Decline Y/Y
by Zacks Equity Research
IQVIA Holdings (IQV) second-quarter 2023 revenues improve year over year.
IQVIA (IQV) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IQVIA Holdings (IQV) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 2.53% and 0.66%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Business Services' Q2 Earnings Lineup on Aug 1: IT, IQV & NSP
by Soumyadeep Bose
Investors interested in the Business Services sector can watch earnings reports of IT, IQV and NSP to be released on Aug 1.
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) revenues are likely to increase year over year on the back of improving segmental performance.
Coursera (COUR) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Coursera (COUR) delivered earnings and revenue surprises of 100% and 5.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Thomson Reuters (TRI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Thomson Reuters (TRI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate IQVIA Holdings (IQV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.